These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29475591)

  • 1. Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.
    Goldstein DS; Holmes C; Lopez GJ; Wu T; Sharabi Y
    Parkinsonism Relat Disord; 2018 May; 50():108-112. PubMed ID: 29475591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
    Goldstein DS; Holmes C; Sullivan P; Jinsmaa Y; Kopin IJ; Sharabi Y
    Parkinsonism Relat Disord; 2016 Oct; 31():79-86. PubMed ID: 27474472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
    Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
    Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy.
    Goldstein DS; Holmes C; Bentho O; Sato T; Moak J; Sharabi Y; Imrich R; Conant S; Eldadah BA
    Parkinsonism Relat Disord; 2008 Dec; 14(8):600-7. PubMed ID: 18325818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac sympathetic denervation predicts PD in at-risk individuals.
    Goldstein DS; Holmes C; Lopez GJ; Wu T; Sharabi Y
    Parkinsonism Relat Disord; 2018 Jul; 52():90-93. PubMed ID: 29032895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies.
    Goldstein DS; Sullivan P; Holmes C; Lamotte G; Lenka A; Sharabi Y
    J Neurochem; 2021 Jul; 158(2):554-568. PubMed ID: 33894018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment.
    Stefani A; Pierantozzi M; Olivola E; Galati S; Cerroni R; D'Angelo V; Hainsworth AH; Saviozzi V; Fedele E; Liguori C
    Neurochem Int; 2017 May; 105():58-63. PubMed ID: 28108196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
    Zubenko GS; Marquis JK; Volicer L; Direnfeld LK; Langlais PJ; Nixon RA
    Biol Psychiatry; 1986 Dec; 21(14):1365-81. PubMed ID: 3024746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy.
    Goldstein DS; Kopin IJ; Sharabi Y; Holmes C
    Clin Auton Res; 2015 Feb; 25(1):61-7. PubMed ID: 25638582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.
    Goldstein DS; Holmes C; Sharabi Y
    Brain; 2012 Jun; 135(Pt 6):1900-13. PubMed ID: 22451506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.
    Baraczka K; Fekete MI; Kanyicska B
    J Neural Transm; 1983; 58(3-4):299-304. PubMed ID: 6420516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
    Lunardi G; Galati S; Tropepi D; Moschella V; Brusa L; Pierantozzi M; Stefani A; Rossi S; Fornai F; Fedele E; Stanzione P; Hainsworth AH; Pisani A
    Parkinsonism Relat Disord; 2009 Jun; 15(5):383-9. PubMed ID: 19010710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
    Thiffault C; Langston JW; Di Monte DA
    Exp Neurol; 2003 Sep; 183(1):173-9. PubMed ID: 12957500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid.
    Loeffler DA; LeWitt PA; DeMaggio AJ; Juneau PL; Milbury PE; Matson WR
    J Neural Transm Park Dis Dement Sect; 1995; 9(1):45-53. PubMed ID: 7605589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease.
    Poceta JS; Parsons L; Engelland S; Kripke DF
    Sleep Med; 2009 Jan; 10(1):129-33. PubMed ID: 18207455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidation of dopamine and related catechols in dopaminergic brain regions in Parkinson's disease and during ageing in non-Parkinsonian subjects.
    Fornstedt Wallin B
    J Neural Transm (Vienna); 2024 Mar; 131(3):213-228. PubMed ID: 38238531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
    Kremer T; Taylor KI; Siebourg-Polster J; Gerken T; Staempfli A; Czech C; Dukart J; Galasko D; Foroud T; Chahine LM; Coffey CS; Simuni T; Weintraub D; Seibyl J; Poston KL; Toga AW; Tanner CM; Marek K; Hutten SJ; Dziadek S; Trenkwalder C; Pagano G; Mollenhauer B
    Mov Disord; 2021 Aug; 36(8):1972-1978. PubMed ID: 33942926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson's Disease: A Cerebrospinal Fluid-Based Study.
    Liguori C; Stefani A; Fernandes M; Cerroni R; Mercuri NB; Pierantozzi M
    J Parkinsons Dis; 2022; 12(2):537-544. PubMed ID: 34864690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography.
    Watson E; Wilk S
    Psychopharmacologia; 1975 Apr; 42(1):57-6. PubMed ID: 1153623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.